The SAM travel vaccines market is segmented into Brazil, Argentina, and the Rest of SAM. During the forecast period, the region is expected to continue its dominance due to an increase in the prevalence of regional diseases, rapid technological innovations, vaccine development, and an increasing geriatric population. Brazil is the major vaccine manufacturer in the region. The country is self-sufficient for 54% of vaccination needs, including DTP, DT for adults and infants, TT, HepB, and DTP combined vaccines (DTP-HB and DTP-HB-Hib), seasonal influenza vaccine, YF vaccine, and meningo AþC. Brazil is one of the major worldwide producers of the YF vaccine, with the lowest market price. Similar to Brazil, Argentina is also the largest country in the region. Argentina has an upper middle-income economy with a diversified industrial sector. The country’s GDP was US$ 123,369 million in 2021. The GDP of Argentina has grown at a compound rate of 6.8% over the last five years. Major countries contributing to the market's growth include Chile, Colombia, Peru, Cuba, Venezuela, and Bolivia. The countries offer significant growth opportunities for the growth of the market. The factors such as increasing focus on vaccine research, continuous advancements in vaccine development technologies, and increasing government spending on pharmaceutical R&D in the region are expected to boost the travel vaccines market.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the SAM travel vaccines market. The SAM travel vaccines market is expected to grow at a good CAGR during the forecast period.
Strategic insights for the South America Travel Vaccines provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
Report Attribute | Details |
---|---|
Market size in 2021 | US$ 143.20 Million |
Market Size by 2028 | US$ 243.85 Million |
Global CAGR (2021 - 2028) | 7.6% |
Historical Data | 2019-2020 |
Forecast period | 2022-2028 |
Segments Covered |
By Product
|
Regions and Countries Covered | South and Central America
|
Market leaders and key company profiles |
The geographic scope of the South America Travel Vaccines refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
SAM travel vaccines market is segmented into product, application, and country. The SAM travel vaccines market, based on product, is segmented into hepatitis A, hepatitis B, meningococcal vaccines, and others. In 2021, the others segment held the largest share of the market. The SAM travel vaccines market, based on application, is segmented into domestic travel and outbound travel. In 2021, the outbound travel segment held the largest share of the market. Based on country, the SAM travel vaccines market is segmented into Brazil, Argentina, and the Rest of SAM.
Abbott; GlaxoSmithKline plc; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; and Sanofi are among the leading companies in the travel vaccines market in the region.
The South America Travel Vaccines Market is valued at US$ 143.20 Million in 2021, it is projected to reach US$ 243.85 Million by 2028.
As per our report South America Travel Vaccines Market, the market size is valued at US$ 143.20 Million in 2021, projecting it to reach US$ 243.85 Million by 2028. This translates to a CAGR of approximately 7.6% during the forecast period.
The South America Travel Vaccines Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South America Travel Vaccines Market report:
The South America Travel Vaccines Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South America Travel Vaccines Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South America Travel Vaccines Market value chain can benefit from the information contained in a comprehensive market report.